Androgenetic Alopecia Clinical Trials
Here are the 6 most popular medical studies for androgenetic alopecia
Dietary Supplement
Nutrafol Women's Balance Hair Growth Supplement +4 More for Alopecia
"This trial aims to show if taking a specific supplement by mouth can help strengthen and promote the growth of thinning hair in both men and women who feel like they have thinning hair."
Popular filter options for androgenetic alopecia trials
Alopecia Areata Clinical Trials
View 23 Alopecia Areata medical studies.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Male Pattern Baldness Clinical Trials
View 15 Male Pattern Baldness medical studies.
Device
iRestore Hair Rejuvenation System for Male Pattern Baldness
The purpose of this study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia
Biological
Platelet Rich Plasma for Male Pattern Baldness
The injection of autologous platelet rich plasma (PRP) is a relatively novel therapy, generating interest across a wide variety of medical specialties, such as orthopedics, dentistry, ophthalmology, and dermatology. Several recently published studies have demonstrated efficacy in treating androgenetic alopecia (aka male or female patterned hair loss), but each varies in the treatment protocol, and there is no evidence-based data to date guiding the dosing parameters of and intervals between injection sessions. We propose a single-center, single-blinded randomized pilot trial to investigate the most beneficial number and frequency ('schedule') of necessary PRP injections in men and women with androgenetic alopecia.
Low Level Laser Therapy
Theradome LH80 PRO for Male Pattern Baldness
This is a prospective, randomized double-blind, multi-center study to evaluate the efficacy of low level laser therapy over-the-counter at home device Theradome LH80 PRO, compared to SHAM for promoting hair growth in males diagnosed with androgenetic alopecia, and a usability study to assess subject ability to self-assess hair loss and understanding use of the device.
Phase 3 Androgenetic Alopecia Clinical Trials
View 69 phase 3 androgenetic alopecia medical studies.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Androgenetic Alopecia Clinical Trials With No Placebo
View 69 androgenetic alopecia medical studies that do not have a placebo group.
Behavioural Intervention
Cold Cap Therapy for Chemotherapy-Induced Hair Loss in Children
This trial will test if the Paxman scalp cooling device is safe and effective in preventing hair loss in pediatric patients receiving chemotherapy for non-cancerous conditions or solid tumors.
View More Androgenetic Alopecia Trials
See another 40 medical studies focused on androgenetic alopecia.
Frequently Asked Questions
Introduction to androgenetic alopecia
What are the top hospitals conducting androgenetic alopecia research?
Hair loss is a common concern for many individuals, particularly those experiencing androgenetic alopecia. Fortunately, several top hospitals are dedicated to unraveling the mysteries of this condition through clinical trials. In New york City, the Icahn School of Medicine at Mount Sinai leads the way with six ongoing trials focused on androgenetic alopecia and a commendable record of 15 previous studies. Their first recorded trial dates back to 2015, showcasing their commitment to finding effective treatments for hair loss. Meanwhile, ForCare Clinical Research in Tampa has made significant strides since initiating their inaugural trial in 2018. Currently conducting five active trials, they have already completed eight investigations into androgenetic alopecia.
The Dawes Fretzin Clinical Research Group LLC in Indianapolis also deserves recognition for its efforts in advancing our understanding of this condition. With four ongoing clinical trials and ten all-time studies under their belt since starting research in 2016, they continue to impact the field positively. Additionally entering the scene is NW Dermatology & Research Center LLC based in Portland where four active androgenetic alopecia trials contribute towards overall scientific knowledge; however theirs remains relatively new having only begun documenting these investigations as recently as 2015.
Notably joining this group is Memorial Sloan Kettering Cancer Center once again demonstrating its versatility by delving into dermatological conditions such as androgenetic alopecia - three ongoing clinical tests further building upon three former experiments from inception during year 2014.These esteemed institutions symbolize hope for individuals grappling with hair loss due to genetic factors like male or female pattern baldness.For them it represents an opportunity not just restore confidence but open doors treatment options that may revolutionize future possibilities- highlighting how medical advancements can reshape lives beyond conventional expectations
Which are the best cities for androgenetic alopecia clinical trials?
For individuals seeking clinical trials for androgenetic alopecia, several cities emerge as frontrunners in research. New york, New York, leads the way with 14 active trials investigating treatments like Dupilumab, CTP-543, and Treatment Group. Portland, Oregon closely follows with 14 ongoing studies focusing on interventions such as Baricitinib and TDM-105795 topical solution. San Antonio, Texas ranks third with 13 active trials studying CTP-543 and Deucravacitinib Dose 1 among others. Across the country in Minneapolis, Minnesota, there are 12 ongoing trials examining PF-06651600 and Baricitinib alongside other potential treatments. Finally, Houston,Texas offers 11 active trials exploring options like Baricitinib and Deucravacitinib Dose 1 along with innovative interventions such as PAXMAN Orbis Scalp Cooler. These cities provide promising opportunities for those interested in participating in cutting-edge clinical research for combating androgenetic alopecia.
Which are the top treatments for androgenetic alopecia being explored in clinical trials?
Clinical trials are actively exploring various treatment options for androgenetic alopecia, a common form of hair loss. Among the top treatments being investigated are:
- PF-06651600: With three active trials dedicated to androgenetic alopecia, this drug has shown promise since its listing in 2016.
- Baricitinib: Listed in 2018, baricitinib is currently involved in two ongoing clinical trials for treating androgenetic alopecia.
- Dupilumab: Also listed in 2018, dupilumab is being studied in two active trials to determine its effectiveness against androgenetic alopecia.
As researchers delve deeper into these potential therapies, there is hope that new solutions may emerge to address the challenges posed by androgenetic alopecia.
What are the most recent clinical trials for androgenetic alopecia?
Exciting advancements in the field of androgenetic alopecia treatment are emerging from recent clinical trials. ADX-914, a promising experimental drug, has shown potential in Phase 2 studies for combating this condition. Farudodstat, Dupilumab, Oral Minoxidil, and TDM-105795 topical solution have also undergone Phase 2 trials with encouraging results. These innovative therapies offer new hope for individuals seeking effective treatments to address androgenetic alopecia's impact on hair loss. With further research and development underway, there is optimism for improved solutions to combat this common condition in the near future.
What androgenetic alopecia clinical trials were recently completed?
Several noteworthy clinical trials for androgenetic alopecia have recently reached completion, presenting promising developments in the search for effective treatments. In April 2022, LEO Pharma concluded a trial investigating Delgocitinib cream. Likewise, in February 2022, Suzhou Kintor Pharmaceutical Inc.'s GT20029 Gel study and Technoderma Medicines Inc.'s TDM-105795 trial were finished. Another TDM-105795 trial by Technoderma Medicines Inc., along with Concert Pharmaceuticals' CTP-543 investigation, wrapped up their respective studies in April 2021 and February 2021. Earlier milestones include Pfizer's Etrasimod trial completed in July 2020 and the University of Arizona's Keratinocyte growth factor study finalized in April 2020. These achievements underscore the dedication of researchers aiming to address the challenges posed by androgenetic alopecia while offering hope to individuals affected by this condition.